오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - maduramicin ammonium - oral powder, pre-mix - maduramicin ammonium antibiotic active 10.0 g/kg - nutrition & metabolism - poultry broilers (meat for human consum) | chickens | chooks | meat birds - coccidiosis | eimeria acervulina | eimeria brunetti | eimeria maxima | eimeria mivati | eimeria necatrix | eimeria tenella

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bec feed solutions pty ltd - 3,5-dinitro-o-toluamide - oral powder, pre-mix - 3,5-dinitro-o-toluamide antiprotozoal active 250.0 g/kg - antibiotic & related - poultry broilers (meat for human consum) | pullet - replacement | turkeys | breeder | broiler breeder | chickens | chooks | meat - caecal coccidiosis | coccidiosis | eimeria acervulina | eimeria brunetti | eimeria maxima | eimeria mivati | eimeria necatrix | eimeria tenella

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - narasin; nicarbazin - oral powder, pre-mix - narasin antibiotic active 80.0 g/kg; nicarbazin urea active 80.0 g/kg - parasiticides - poultry broilers (meat for human consum) | chickens | chooks | meat birds - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - nicarbazin - oral powder, pre-mix - nicarbazin urea active 250.0 g/kg - nutrition & metabolism - poultry broilers (meat for human consum) | chickens | chooks | meat birds - coccidiosis | eimeria acervulina | eimeria brunetti | eimeria maxima | eimeria mivati | eimeria necatrix | eimeria tenella

유럽 연합 - 영어 - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. 

유럽 연합 - 영어 - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

뉴질랜드 - 영어 - Ministry for Primary Industries

phibro animal health pty limited - salinomycin sodium - salinomycin sodium 120 g/kg - coccidiostat

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

griffin corporation australia pty ltd - copper as cupric (ii) hydroxide - fungicide - almond | apple crop = apple orchard | apricot | avocado | banana | bean | brassica spp. or cole crop | capsicum or pepper | carr - algae | alternaria leaf blight or spot blight | angular leaf spot on cucurbit | angular leaf spot-p. syringae pv. tabaci | anthracnose - colletotrichum spp. | anthracnose on pawpaw, mango or avocado | anthracnose or ring spot on lettuce | ascochyta blight or black stem on pea | bacterial black spot | bacterial brown spot | bacterial canker | bacterial canker on tomato | bacterial gummosis | bacterial leaf spot on lettuce | bacterial speck | bacterial spot - x. campestris pv. pruni | bacterial spot blight | bacterial spot on capsicum | bacterial spot on cucurbit | bacterial spot on tomato | black rot on cole crop/brassica | black spot on citrus | black spot/scab in apple/pear | cersospora leaf blight or spot | chocolate spot on bean | citrus melanose | common blight | crown top rot | downy mildew - peronospora spp. | downy mildew on allium (onion, garlic) | downy mildew on cole crop/brassica | downy mildew on grape | downy mildew on lettuce | downy mildew on rhubarb | early blight or target blackspot | freckle

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

griffin corporation australia pty ltd - copper as cupric (ii) hydroxide - fungicide - almond | apple crop = apple orchard | apricot | avocado | banana | bean | brassica spp. or cole crop | capsicum or pepper | carr - algae | alternaria leaf blight or spot blight | angular leaf spot on cucurbit | angular leaf spot-p. syringae pv. tabaci | anthracnose - colletotrichum spp. | anthracnose on pawpaw, mango or avocado | anthracnose or ring spot on lettuce | ascochyta blight or black stem on pea | bacterial black spot | bacterial brown spot | bacterial canker | bacterial canker on tomato | bacterial gummosis | bacterial leaf spot on lettuce | bacterial speck | bacterial spot - x. campestris pv. pruni | bacterial spot blight | bacterial spot on capsicum | bacterial spot on cucurbit | bacterial spot on tomato | black rot on cole crop/brassica | black spot on citrus | black spot/scab in apple/pear | cersospora leaf blight or spot | chocolate spot on bean | citrus melanose | common blight | crown top rot | downy mildew - peronospora spp. | downy mildew on allium (onion, garlic) | downy mildew on cole crop/brassica | downy mildew on grape | downy mildew on lettuce | downy mildew on rhubarb | early blight or target blackspot | freckle

나이지리아 - 영어 - NAFDAC (National Agency for Food and Drugs Administration and Control)

copper hydroxide 538gm/kg